Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes

Scandinavian Journal of Immunology

Volumn 45, Issue 2, 1997, Pages 182-192

  Maeurer, M J ^a,b,c   Walter, W ^a   Martin, D ^a   Zitvogel, L ^a,b   Elder, E ^b   Storkus, W ^a,b   Lotze, M T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 7; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0001304588     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-384.x     Document Type: Article

References (52)

1. Reynolds T. Issues remain for treating colorectal cancer. J Natl Cancer Inst 1995;87:480-1.
2. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings. JAMA 1986;256:3117-24.
3. Rosenberg SA, Packard B, Aebersold PM et al. Immunotherapy of patients with metastatic melanoma using tumour infiltrating lymphocytes and interleukin-2. N Engl J Med 1988;319:1676-80.
4. Andersen SN, Rogum TO, Lund, E, Meling GGI, Hauge S. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993;68:80-5.
5. Banner BF, Savas L, Baker S, Woda, BA. Characterization of the inflammatory cell populations in normal colon and colonic carcinomas. Virchows Archiv 1993;64:213-20.
6. Banner SF, Samez-Alpna, E, Yousem SA. An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Modern Pathol 1993;6:295-301.
7. Ransom JH, Pelle B, Hanna Jr MG. Expression of class II major histocompatibility complex molecules correlates with human colon-tumour - vaccine efficay. Cancer Res. 1992;52:3460-6.
8. Garrido FT, Cabrera A, Concha S, Glew F, Ruiz-Cabello F, Stern PL. Natural history of HLA-expression during tumour development. Immunol Today 1993;14:491-9.
9. Ostenstad B, Schlichting LT, Harboe M. Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45 RO molecule showing a primed population of lymphocytes in the tumour area. Gut 1994;35:382-7.
10. Ostenstad B, Sioud M, Schlichting LT, Harboe M. Limited heterogeity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours. Br J Cancer 1993;69:1078-82.
11. Hoover Jr. HC, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer - 6.5.year median follow-up of a phase-III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
12. Hoover Jr HC, Surdyke MG, Dangel RB, Peters LC, Hanna Jr M. Delayed cutaneous hypernsensivity to autologous tumour cells n colorectal cancer patients immunized with an autologous tumour cell Bacillus Calmette-Guerin vaccine. Cancer Res. 1984;44:1671-76.
13. Ransom JH, Pelle BA, Hubers H, Keynton LM, Hanna Jr M, Pomato N. Identification of colon-tumour associated antigens by T-cell lines derived from tumour infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumour-cell/Bacillus Calmette-Guerin vaccine. 1993. Int J Cancer 1993;54: 734-40.
14. Fossum B T, Gedde-Dahl II J, Breivik JA et al. p21-ras-, peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation. (13Gly > Aps). Intern J Cancer 1994;56:40-5.
15. Geede-Dahl II T, Spurkland A, Erikson JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras- derived synthetic peptides. Hum Immunol 1992;33:266-72.
16. Jung S, Schleusner HJ. Human T lymphocytes recognize a peptide of single point-mutated oncogenic ras protein. J Exp Med 1991;173: 273-79.
17. Hom SA, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumour by lymphocytes infiltrating coloncarcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993; 36:1-8.
18. Poussier P, Julius M. Thymus independent T cell development and selection in the intestinal epithelium. Annu Rev Immunol 1994;12: 521-33.
19. Gutierrez JC, Palacios R. Heterogeneity of thymic epithelial cells in promoting T-lymphocytes differentiation in vivo. Proc Natl Acad Sci USA 1991;88:642-6.
20. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine activated killer cells from human peripheral blood. J Exp Med 1990; 172:577-87.
21. Alderson MR, Tough TW, Ziegler SF, Grabstein KH. Interleukin-7 induces cytokine secretion and tumouricidal activity by human peripheral blood monocytes J Exp Med 1991;173:923-30.
22. Samaridis J, Casorati G, Traunecker A et al. Development of lymphocytes in interleukin 7 transgenic mice. Eur J Immunol 1991;21:453-60.
23. Lotze MT, Zeh III HJ, Elder EM et al. Use of T cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T cell reactivity to melanoma. J Imunother 1992;12:212-17.
24. Stotter H, Custer MC, Bolon ES, Guedez L, Lotze MT. Interleukin-7 induces human lymphokine activated killer (LAK) cells and is regulated by interleukin-4. J Immunol 1991;146:150-64.
25. Heufler C, Topar G, Grasseger A et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med 1993;178:1109-14.
26. Vicari A, de Moraes C, Gombert JM et al. Interleukin 7 induces preferential expansion of V beta 8.2+CD4-8- and V beta 8.2+CD4+8-murine thymocytes positively selected by class I molecules. J Exp Med 1994;180:653-61.
27. Appasamy PM, Kenniston Jr TW, Weng Y, Holt EC, Kost J, Chambers WH. Interleukin-7 induced expression of specific T cell receptor gamma variable regions in murine fetal liver cultures. J Exp Med 1993;178:2201-6.
28. Elder EM, Whiteside TL. Processing of tumours for vaccine and / or tumour infiltrating lymphocytes. In: Rose NR, Conway de Macaio E, Fahey JL, Friedman H, Penn GM (eds.) Manual of Clinical Laboratory Immunology, 4th ed. American Society for Microbiology, 1992; 817-19.
29. Skeen MJ, Ziegler HK. Intercellular interaction and cytokine responsiveness of peritoneal αβ and γδ T cells from listeria-infected mice: Synergistic effects of interleukin 1 and 7 on γδ T cells. J Exp Med 1993;178:985-96.
30. Skeen MJ, Ziegler HK. Induction of murine peritoneal gamma/delta T cells and their role in bacterial infection. J Exp Med 1993;178: 971-84.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
32. Thiele DL, Lipsky PE. The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells. Immunol Today 1989;10:375-81.
33. Books CG, Urdal DL, Henney CS. Lymhokine driven 'differentiation' of cytotoxic T cell clones into cells with NK like specificity: Correlation with display of membrane macromolecules. Immunol Rev 1983;72:43-72.
34. Namen AE, Lutpon S, Hjerrild K et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988;333: 571-4.
35. Goodwill RG, Lupton S, Schmierer A et al. Human interleukin 7. Molecular cloning and growth Factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA 1989;86:302-7.
36. Sieling PA, Sakimura L, Uyemura K et al. IL-7 in the cell mediated immune response to a human pathogen. J Immunol 1995;154: 2775-83.
37. Benjamin D, Sharma V, Knohloch TJ, Armitage RJ, Dayton MA, Goodwill RG. B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol 1994;152:4749-57.
38. Du XX, Doerschuk CM, Orazi A, Williams DA. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994; 83:33-7.
39. Grabstein KH, Eisenman J, Shanebeck K et al. Cloning of a novel T cell growth factor which interacts with theβ chain of the interleukin-2 receptor. Science 1994;264:2822-6.
40. Wessell D. A less toxic IL-2 analogue? The investigation of interleukin-15. Cope, Working in Oncology 1995;6-10.
41. Matsue H, Bergstresser PR, Takahashima A. Keratinocytes-derived IL-7 serves as a growth factor for dendritic epidermal T cells in mouse skin. J Immunol 1993;151:6012-18.
42. Matsue H, Cruz Jr PD, Bergstresser PR, Takashima A. Cytokine expression by epidermal cell subpopulations. J Invest Dermatol 1992;99:42-8.
43. Ariizumi K, Meng Y, Bergstresser PR, Takashima A. IFN-γ-dependent IL-7 gene regulation in keratinocytes. J Immunol 1995;154: 6031-9.
44. Ippoliti G, Piazza P, Spada M et al. Serum cytokine levels after small bowel tranplantation (SBT) in pigs. Influence of FK506 treatment. Transpl Proc 1994;26:1562-3.
45. Bohm M, Moller P, Kalbfleisch U, Worm M, Czaenetzki BM, Schadendorf D. Lysis of allogeneic and autologous melanoma cells by IL-7 induced lymphokine-activated killer cells. Br J Cancer 1994;70:54-9.
46. Miller AR, McBride WH, Dubinett SM et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene tranfer: comparison of immunologic properties with interleukin-2. Blood 1993;82:3683-94.
47. Sica D, Rayman P, Stanley J et al. Interleukin 7 enhances the proliferation and effector function of tumour-infiltrating lymphocytes from renal cell cancer. Intern J Cancer 1993;53:941-47.
48. Carini C, Essex M. Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune responses of HIV-1 infected individuals. AIDS Res & Hum Retrovir 1994;10:121-30.
49. Cohen PA, Kim H, Fowler DH et al. Use of interleukin-7, interleukin-2 and interferon-gamma to propagate CD4+ T-cells in culture with maintained antigen specificity. J Immunother 1993;14:242-52.
50. Lynch DE, Miller RE. Interleukin 7 promotes long-term in vitro growth of anti tumour cytotoxic T lymphocytes with immunotherapeutic efficay in vivo. J Exp Med 1994;179:31-42.
51. Hoskin DW, Reynolds T, Blay J. Colon adenocarcinoma cells inhibit anti-CD3-activated killler cell induction. Cancer Immunol Immunother 1994;48:201-7.
52. Murphy WJ, Back TC, Conlon KC et al. Antitumour effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest 1993;92:1918-24.